Astria Therapeutics
ATXS
ATXS was delisted on the 22nd of January, 2026.
68 hedge funds and large institutions have $171M invested in Astria Therapeutics in 2023 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 27 increasing their positions, 18 reducing their positions, and 12 closing their positions.
50% more repeat investments, than reductions
Existing positions increased: 27 | Existing positions reduced: 18
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
6.04% less ownership
Funds ownership: 88% → 81.96% (-6%)
11% less funds holding
Funds holding: 76 → 68 (-8)
17% less capital invested
Capital invested by funds: $205M → $171M (-$34M)
40% less call options, than puts
Call options by funds: $61K | Put options by funds: $102K
67% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 12
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SVCM
Saturn V Capital Management
Austin,
Texas
|
+$4.96M |
| 2 |
TLP
Tri Locum Partners
New York
|
+$3.19M |
| 3 |
AAA
Affinity Asset Advisors
New York
|
+$2.98M |
| 4 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
+$1.43M |
| 5 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
+$934K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$8.33M |
| 2 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
-$5.62M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$3.39M |
| 4 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$2.54M |
| 5 |
Millennium Management
New York
|
-$2.3M |
ATXS Hedge Fund Activity: Q3 2023 in Review
68 of the 6,302 institutional investors tracked by Wall St. Rank reported a position in Astria Therapeutics (ATXS) for Q3 2023, worth a combined $171M — down 17% from $205M a quarter earlier.
Sellers outnumbered buyers: 12 funds closed out of ATXS and 4 opened new positions — a net loss of 8 holders — while 18 trimmed existing stakes and 27 added.
The largest buyer was Saturn V Capital Management, adding an estimated $4.96M. The largest seller was Cormorant Asset Management, exiting entirely with an estimated $8.33M sold.
- 68 institutional investors held Astria Therapeutics (ATXS) as of Q3 2023, down from 76 in Q2 2023.
- Funds reported $171M of Astria Therapeutics stock for Q3 2023, down 17% quarter-over-quarter.
- 4 funds opened new Astria Therapeutics positions in Q3 2023 and 12 closed out, a net change of -8 holders.
- The largest Astria Therapeutics buyer in Q3 2023 was Saturn V Capital Management, an estimated $4.96M added.
- The largest Astria Therapeutics seller in Q3 2023 was Cormorant Asset Management, an estimated $8.33M sold.
Based on aggregated 13F filings for Q3 2023.